At the 24th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub spoke to Mohamad Mohty from the Hôpital Saint-Antoine, Paris, FR, about the role of autologous stem cell transplant (ASCT) in the future treatment of multiple myeloma (MM).
In this video, Professor Mohty summarizes the current status of ASCT in myeloma, stating it is a core part of the treatment pathway. He discuses smoldering myeloma, options for induction regimens, and then the potential future maintenance strategies that may impact patient care. Professor Mohty specifically refers to the potential of daratumumab, administered once every other month, to replace lenalidomide as maintenance therapy following ASCT. Professor Mohty concludes we will have to wait for the trial results, but that myeloma is "on the podium" at this year's EHA conference, with many interesting abstracts to be presented.